Home › Chembio Inks Commercialization Deal for Dengue, Zika, Chikungunya Tests

Chembio Inks Commercialization Deal for Dengue, Zika, Chikungunya Tests

May 24, 2018

NEW YORK (360Dx) – Chembio Diagnostics announced today that it has signed an agreement to commercialize its point-of-care tests for Dengue, Zika, and Chikungunya infection in Brazil with Bio-Manguinhos.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Jul
19
Featured Webinar

Advances in NGS for Ultra-High Sensitivity Applications in Translational and Clinical Research

Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research. 

Jul
25
Featured Webinar

Antibiotic Gene Surveillance: What You Don’t See Can Hurt You!

Sponsored by
Streck

This online seminar will discuss the advantages of incorporating molecular testing into the microbiology laboratory to aid in the identification of relevant antibiotic resistance mechanisms. 

What's Popular?

In Infectious Disease

  1. FDA Clears DiaSorin HSV Assay for Extended Swab Sample Claims

  2. UK Researchers, BioMérieux, Bioaster Developing TB Assay Based on Host Gene Signature

    Premium

  3. NEJM Study Results Spark Clinician Debate on Procalcitonin Testing to Guide Antibiotic Use

    Premium

  4. MDx Systems Integrate LDTs With IVD Kits for Labs Seeking Greater Efficiency

    Premium

  5. UK Researchers Develop Rapid POC Test for Antibiotic-Related Hearing Loss

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.